By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The stock prices of both Caliper Life Sciences and Illumina increased more than 100 percent in 2010, as the GWDN Index produced strong gains for the second year in a row amid a recovering broader market.

Overall, only nine of the 32 stocks listed in the GWDN Index below finished the year below their price at the end of 2009, with Vermillion and CombiMatrix dropping the most during the year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.